Atishoo! Atishoo! They all cash in

A flu epidemic is good news for a company with a 'wonder drug' in the lab. Liz Hunt looks behind the hype

Nobles at the courts of Queen Elizabeth I and Mary Queen of Scots referred to it as the "newe acquaintance". In 1568, a Thomas Willis said that it appeared to be sent "by some blast of stars", and in 1775 it was reported that 20,000 people had been "seized in one night".

More than 200 years later influenza is still grabbing headlines. One of the most common and debilitating of global infections, the virus can have a devastating impact on industry, schools and hospitals. Millions of pounds have been invested in trying to beat it, but so far it has defied the best efforts of scientists. So when a new flu cure is mooted, it is guaranteed column inches.

With an eagle eye on its share price, Glaxo Wellcome has seized the opportunity presented by reports of a pre-Christmas epidemic to hype a new potential flu drug, one which is scarcely out of the laboratory.

The company says that a poor flu season last year hampered the development of the compound, known as GG167. There were too few cases to try it on. But this year, the company says confidently, the surge in cases of flu and flu-like illness now being reported has presented the ideal conditions for large-scale clinical trials. It predicts approval from regulatory authorities for a nasal spray or inhalation as early as 1997, with sales in its first year in excess of pounds 200m.

Such confidence in a drug which has been tested in just a handful of human volunteers so far - very few of whom actually had flu - has alarmed drug industry observers and leading scientists. They see a trend developing in which British pharmaceutical companies, once a model of caution, are making claims for compounds still in the preliminary stages of development.

The reasons are clear. The executives of British companies are desperate to retain their dominant position in the global market place, and time is running out. They need new products to replace their top sellers - drugs like Zantac, an anti-ulcer treatment and the best selling drug in the world, but one which loses its patent exclusivity in less than two years' time. Drug companies believe that the "hyping" strategy persuades shareholders to keep the faith. British Biotech, a relatively new company, last week saw its share price shoot up by more than 50 per cent after releasing results of a new anti-cancer drug. The drug, marimastat, had been tested in just 94 patients for one month only.

GG167 is certainly a novel approach to combating the influenza virus. The computer-designed drug does not kill it, but appears to stop the virus in its tracks. It blocks an enzyme, neuraminidase, which is essential for the release of the virus from infected human cells in the nasal passage and the airways of the lungs. The theory is that the immune system will then "mop up" these infected cells and so prevent their spread through the rest of the body.

Peter Collins, a scientist at Monash University in Melbourne, Australia, is credited with discovering GG167 in the mid-Eighties. However, the compound belongs to a much older group of chemicals developed in the Sixties by Peter Palese, a chemist in Vienna. He recognised their potential as anti- viral drugs, but Collins, an X-ray crystallographer, was the one to "fine- tune" the original molecule until it was specific for strains A and B of the flu virus - the most common strains in circulation - sticking to them at a particular point and inhibiting neuraminidase.

Palese's molecule was boat-shaped and fitted a groove in the viral structure neatly enough, according to Professor John Oxford, a leading virologist at the Royal London Hospital in Whitechapel. "What Collins did was add a little oar shape to the molecule so that it fitted even better and had greater efficacy against the virus," he explains.

In the test tube and in laboratory animals, GG167 has proved successful, but in humans there is little in the way of conclusive evidence. Other similar neuraminidase inhibitors are being developed in labs around the world, and there is fierce competition to be first on the market. However, many virologists believe that a simpler back-to-basics approach, now being applied to the Aids virus, is the only way forward against flu: better drugs to treat the symptoms are a more cost-effective option than millions of pounds being invested in potential cures.

But other doctors point to an existing drug as the most exciting prospect for treating influenza A, the most dangerous strain of the virus and the one associated with most fatalities. The drug is amantadine, made by Ciba Geigy and sold as Symmetrel. It is better known as a treatment for Parkinson's disease but its value in flu is widely recognised by those in the know. It is, however, underused because few GPs have heard of it and the Department of Health is not keen to promote it. Flu vaccination for those at particular risk stretches the NHS budget enough as it is. The department has, according to some doctors, overemphasised its side-effects, described as an excess of "jittery" feelings.

A related drug, rimantadine, would reduce these minor side-effects even further, it is claimed. It is rarely used in the West but doctors in the former Soviet Union have regularly prescribed it and have a wide base of patient experience. A few Western drug companies have expressed interest but refuse to comment on its potential as a flu treatment just yet. It is, however, a more realistic option than a hi-tech, state-of-the-art compound which, so far, has proved itself effective at relieving flu symptoms only in laboratory rats and mice.

PROMOTED VIDEO
Have you tried new the Independent Digital Edition apps?
News
ebookA unique anthology of reporting and analysis of a crucial period of history
News
Ian Thorpe had Rio 2016 in his sights
people
Arts and Entertainment
Original Netflix series such as Orange Is The New Black are to benefit from a 'substantial' increase in investment
TVHoax announcement had caused outrage
Life and Style
Swimsuit, £245, by Agent Provocateur
fashion

Diving in at the deep end is no excuse for shirking the style stakes

News
One Direction star Harry Styles who says he has no plans to follow his pal Cara Delevingne down the catwalk.
peopleManagement confirms rumours singer is going it alone are false
Voices
Mrs Brown's Boy: D'Movie has been a huge commercial success
voicesWhen it comes to national stereotyping, the Irish know it can pay to play up to outsiders' expectations, says DJ Taylor
Arts and Entertainment
Curtain calls: Madani Younis
theatreMadani Younis wants the neighbourhood to follow his work as closely as his audiences do
Arts and Entertainment
'Deep Breath' is Peter Capaldi's first full-length adventure as the twelfth Doctor
TVFirst episode of new series has ended up on the internet
Life and Style
Douglas McMaster says the food industry is ‘traumatised’
food + drinkSilo in Brighton will have just six staple dishes on the menu every day, including one meat option, one fish, one vegan, and one 'wild card'
Sport
Mario Balotelli, Divock Origi, Loic Remy, Wilfried Bony and Karim Benzema
transfersBony, Benzema and the other transfer targets
Independent
Travel Shop
the manor
Up to 70% off luxury travel
on city breaks Find out more
santorini
Up to 70% off luxury travel
on chic beach resorts Find out more
sardina foodie
Up to 70% off luxury travel
on country retreats Find out more
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

C# Developer (ASP.NET, F#, SQL, MVC, Bootstrap, JavaScript)

£55000 - £65000 per annum + Benefits + Bonus: Harrington Starr: C# Developer (...

C# Payment Developer (Swift, FOX, Vigil, .NET, SQL)

£55000 - £65000 per annum + Benefits + Bonus: Harrington Starr: C# Payment Dev...

Information Security Manager (ISO 27001, Accreditation, ITIL)

£70000 per annum: Harrington Starr: Information Security Manager (ISO 27001, A...

C# Developer (HTML5, JavaScript, ASP.NET, Mathematics, Entity)

£30000 - £45000 per annum + Benefits + Bonus: Harrington Starr: C# Developer (...

Day In a Page

Iraq crisis: How Saudi Arabia helped Isis take over the north of the country

How Saudi Arabia helped Isis take over northern Iraq

A speech by an ex-MI6 boss hints at a plan going back over a decade. In some areas, being Shia is akin to being a Jew in Nazi Germany, says Patrick Cockburn
The evolution of Andy Serkis: First Gollum, then King Kong - now the actor is swinging through the trees in Dawn of the Planet of the Apes

The evolution of Andy Serkis

First Gollum, then King Kong - now the actor is swinging through the trees in Dawn of the Planet of the Apes
You thought 'Benefits Street' was controversial: Follow-up documentary 'Immigrant Street' has got locals worried

You thought 'Benefits Street' was controversial...

Follow-up documentary 'Immigrant Street' has got locals worried
Refugee children from Central America let down by Washington's high ideals

Refugee children let down by Washington's high ideals

Democrats and Republicans refuse to set aside their differences to cope with the influx of desperate Central Americas, says Rupert Cornwell
Children's books are too white, says Laureate

Children's books are too white, says Laureate

Malorie Blackman appeals for a better ethnic mix of authors and characters and the illustrator Quentin Blake comes to the rescue
Blackest is the new black: Scientists have developed a material so dark that you can't see it...

Blackest is the new black

Scientists have developed a material so dark that you can't see it...
Matthew Barzun: America's diplomatic dude

Matthew Barzun: America's diplomatic dude

The US Ambassador to London holds 'jeans and beer' gigs at his official residence – it's all part of the job, he tells Chris Green
Meet the Quantified Selfers: From heart rates to happiness, there is little this fast-growing, self-tracking community won't monitor

Meet the 'Quantified Selfers'

From heart rates to happiness, there is little this fast-growing, self-tracking community won't monitor
Madani Younis: Five-star reviews are just the opening act for British theatre's first non-white artistic director

Five-star reviews are just the opening act for British theatre's first non-white artistic director

Madani Younis wants the neighbourhood to follow his work as closely as his audiences do
Mrs Brown and her boys: are they having a laugh?

Mrs Brown and her boys: are they having a laugh?

When it comes to national stereotyping, the Irish – among others – know it can pay to play up to outsiders' expectations, says DJ Taylor
Gavin Maxwell's bitter legacy: Was the otter man the wildlife champion he appeared to be?

Otter man Gavin Maxwell's bitter legacy

The aristocrat's eccentric devotion to his pets inspired a generation. But our greatest living nature writer believes his legacy has been quite toxic
Joanna Rowsell: The World Champion cyclist on breaking her collarbone, shattering her teeth - and dealing with alopecia

Joanna Rowsell: 'I wear my wig to look normal'

The World Champion cyclist on breaking her collarbone, shattering her teeth - and dealing with alopecia
Bill Granger recipes: Our chef gives raw ingredients a lift with his quick marinades

Bill Granger's quick and delicious marinades

Our chef's marinades are great for weekend barbecuing, but are also a delicious way of injecting flavour into, and breaking the monotony of, weekday meals
Germany vs Argentina World Cup 2014 preview: Why Brazilians don't love their neighbours Argentina any more

Anyone but Argentina – why Brazilians don’t love their neighbours any more

The hosts will be supporting Germany in today's World Cup final, reports Alex Bellos
The Open 2014: Time again to ask that major question - can Lee Westwood win at last?

The Open 2014

Time again to ask that major question - can Lee Westwood win at last?